Characteristics of cognitive impairment in adult asymptomatic moyamoya disease

Shihao He(Capital Medical University), Rong Wang(Capital Medical University), Xun Ye(Capital Medical University), Junshi Shao(Capital Medical University), Ziqi Liu, Li Yan Yuan(Beijing Normal-Hong Kong Baptist University), Ran Duan(Peking University), Li Tian(Beijing Normal University), Shusen Qin(Capital Medical University), Cunxin Tan(Peking University)
BMC Neurology
August 31, 2020
10.1186/s12883-020-01898-8
Cited by 39

Related Papers

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
|New England Journal of Medicine|2015|241
Artificial intelligence in educational assessment: ‘Breakthrough? Or buncombe and ballyhoo?’
|Journal of Computer Assisted Learning|2021|191
Association between white matter impairment and cognitive dysfunction in patients with ischemic Moyamoya disease
|BMC Neurology|2020|30
Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
|Cancer Research|2020|30
Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease
|Stroke|2023|30